Compare iShares MBS ETF (MBB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Merck & Co., Inc. — how do they compare? iShares MBS ETF trades at $89.71 (market cap $35.41B), while Merck & Co., Inc. trades at $146.06 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 9.9× iShares MBS ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Merck & Co., Inc. for 98 Days on average.
| MBB | MRK | |
|---|---|---|
Market Cap | $35.41B | $351.28B |
Volume | 5,388,525 | 7,969,665 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $156.43 |
52-Week Low | $89.09 | $82.49 |
Typical Hold Time | 96 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.68, up 0.52% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock recently hit a new 52-week low of $91.02 on September 15, 2026, as short interest surged 98.3% in September, reflecting negative sentiment. Recent news highlights concerns over rising intermediate-term rates and inflation pressures impacting mortgage-backed securities.
The outlook remains cautious due to interest rate sensitivity and convexity risks in the mortgage market. While institutional buying by firms like Corient Private Wealth provides some support, the bearish technicals and macroeconomic headwinds suggest limited near-term upside. Key risks include further rate hikes and prepayment volatility in the MBS portfolio.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
